The Alfred Hosptial Trials

The Alfred Hosptial	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Schwarer, Anthony P

PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

	Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Initiation of new trial in Ph+ ALL
	Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL

Active, not recruiting

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

Tuxen, David

ACTRN12606000268549: The cardiac and respiratory response to recruitment maneuvers (RM) in ventilated patients with acute lung injury.

Completed

1/2

Monash University, Monash University

Acute lung injury, Acute respiratory distress syndrome (ARDS)

ACTRN12611000304932: Detection, quantification and differentiation of upper and lower airway obstruction during mechanical ventilation

Not yet recruiting

N/A

Intensive care department, Intensive care department

Lung Disease COAD Asthma

Voskoboynik, Mark

NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting

496

Europe, US, RoW

Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Jiangsu HengRui Medicine Co., Ltd.

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

12/26

ENZA-p, NCT04419402: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting

162

RoW

Lu-PSMA, 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA, Enzalutamide, Xtandi

Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council, Clinical Trials Centre, Prostate Cancer Research Alliance, Endocyte, Astellas Pharma Inc

Metastatic Castration-Resistant Prostate Cancer

07/24

01/25

EVOLUTION, NCT05150236: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Active, not recruiting

RoW

177Lu-PSMA-617, 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA, Ipilimumab, YERVOY, Nivolumab, OPDIVO

Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Prostate Cancer Foundation of Australia, Bristol-Myers Squibb, Advanced Accelerator Applications, University of Sydney

Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Prostate Cancer, Neoplasms by Site, Neoplasms, Prostatic Disease

08/24

12/24

ERASER, NCT04305249: Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

Terminated

RoW

ATG-017, AZD0364 hemi-adipic acid, ATG-017+Nivolumab, AZD0364 hemi-adipic acid+Opdivo

Antengene Therapeutics Limited, Bristol-Myers Squibb

Solid Tumor, Hematological Malignancy

04/24

05/24

SHR-A1811-I-101, NCT04446260: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Active, not recruiting

396

US, RoW

SHR-A1811

Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd.

Advanced Solid Tumors

12/25

03/26

NCT05252364: A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed

RoW

HP518 - Dose Escalation, HP518 - Dose expansion

Hinova Pharmaceuticals Aus Pty Ltd

Metastatic Castration-resistant Prostate Cancer

01/24

REPAIR, NCT05425862: Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Suspended

RoW

Pidnarulex, CX-5461, Talazoparib

Peter MacCallum Cancer Centre, Australia

Metastatic Castration Resistant Prostate Cancer (mCRPC)

07/24

12/25

NCT06341647: Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Not yet recruiting

RoW

AB-201, Cyclophosphamide, Fludarabine

GC Cell Corporation

Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

04/27

02/29

NCT06092580: Phase 1 Study of AWT020 in Advanced Cancer

Recruiting

RoW

AWT020

Anwita Biosciences

Advanced Cancer

02/25

09/25

KEYNOTE-E80, NCT05957081: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309

Not yet recruiting

RoW

PMC-309 monotherapy, Monotherapy, PMC-309 Dose Escalation in Combination with Pembrolizumab, Combination Therapy, PMC-309 Dose Expansion, Mono and Combination therapy

PharmAbcine, Novotech (Australia) Pty Limited, Merck Sharp & Dohme LLC

Advanced or Metastatic Solid Tumors

09/25

10/28

PROBE, NCT04986865: A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Recruiting

US, RoW

ATG-101

Antengene Biologics Limited

Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma

10/25

01/26

NCT05906862: AMT-253 in Patients With Selected Advanced Solid Tumours

Recruiting

RoW

AMT-253

Multitude Therapeutics (Australia) Pty Ltd

Advanced Solid Tumor

10/25

02/26

Nichol, Alistair

REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting

20000

Europe, Canada, Japan, US, RoW

Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir

UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore

Community-acquired Pneumonia, Influenza, COVID-19

02/26

02/28

TTM-2, NCT02908308: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

Completed

N/A

1900

Europe, US, RoW

Targeted temperature management to 33°C, Standard care with early treatment of fever

Helsingborgs Hospital, Lund University, Region Skåne - Skånevård SUND, Copenhagen Trial Unit, Center for Clinical Intervention Research, Clinical Trials Sweden, Forum South, Integrated Biobank of Luxembourg

Out-of-hospital Cardiac Arrest

06/22

12/22

ROSETTA, NCT05814094: Red Blood Cell Transfusion in ECMO - a Feasibility Trial

Recruiting

N/A

120

RoW

Red Blood Cell Transfusion

Australian and New Zealand Intensive Care Research Centre

Blood Loss Anemia, Extracorporeal Membrane Oxygenation Complication, Disability Physical, Cognitive Ability, General, Functional Status

12/24

03/25

SPRINT-SARI, NCT02498587: Short Period Incidence Study of Severe Acute Respiratory Illness

Recruiting

N/A

15000

RoW

Australian and New Zealand Intensive Care Research Centre, International Severe Acute Respiratory and Emerging Infection Consortium, The International Forum of Acute Care Trialists

Severe Acute Respiratory Infection

12/26

Patil, Sushrat

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites